Leon Aarons, Mats Karlsson, France Mentré, Ferdinand Rombout, Jean-Louis Steimer and Achiel van Peer.
Role of modelling and simulation in Phase I drug development
|
Stuart Beal
Things you may have wanted to ask about the $ESTIMATION record but have been hesitant to ask
|
Didier Concordet
Checking departure from normality of the random effect
|
Stephen Duffull1,2, France Mentré3, Leon Aarons1
Optimal Design Of A Population Pharmacodynamic Experiment
|
David Giltinan
Population PK/PD Modeling In Drug Development: A Case Study
|
Pascal Girard1,2, Silvy Laporte-Simitsidis3, Sylvie Chabaud1
Multilevel nested random effect model implementation
|
Roberto Gomeni, Vincenzo Teneggi, Laura Iavarone, Lisa Squassante, and Alan Bye.
Population PK/PD Of Craving Symptoms In An Enforced Smoking Cessation Population: Probabilistic And Indirect Modelling Approach.
|
Mentré F, Escolano S
Validation Methods In Population Pharmacokinetics: A New Approach Based On Predictive Distributions With An Evaluation By Simulation
|
Sylvie Retout1, France Mentré1 & René Bruno2
Optimal population designs for enoxaparin pharmacokinetics: evaluation by simulation
|
Rik C. Schoemaker, I. Ruys-Dudok van Heel, M.M.J. van der Vorst, J.E. Kist-van Holthe tot Echten, J. Burggraaf & A.F. Cohen.
In Search of an Optimal Furosemide Infusion Strategy in Children after Cardiac Surgery Using Modelling and Simulation
|
Alison H Thomson
Population Pharmacokinetics in Paediatric Patients; the Good, the Bad and the Ugly
|
Iñaki F. Trocóniz1, Santos Armenteros2, María V. Planelles3, Ju lio Benítez4, Rosa Domínguez2
Pharmacokinetic/Pharmacodynamic Modeling of the Antipyretic Effect of Two Oral Formulations of Ibuprofen: Suspension and Effervescent Granules
|
B. Vrijens and E. Goetghebeur
The impact of patient compliance in pharmacokinetic/pharmacodynamic studies
|
Paul J. Williams
The Application of Resampling Methods to Population Pharmacokinetic Modeling
|
Yoshitaka Yano, Stuart Beal, Lewis B. Sheiner
Evaluating Pharmacokinetic/Pharmacodynamic Models Using The Posterior Predictive Check
|
Peregrina-Lucano A.A.1,2, Martín-Suárez A.1, García L.R.2, González M.H.2, Garcia M.J.1, Lanao J.M.1
Comparative study of NONMEM and WinNonMix in the population pharmacokinetics of benznidazol
|
Eugène Cox, Eric Snoeck & Jaap Mandema
Population pharmacodynamic model for count data: Application to clinical trial simulations for compound PH2000 for the improvement of the number of satisfying events.
|
Frey, N., Laveille, C. and Jochemsen, R.
Effect of Quinidine on the Pharmacokinetics and Pharmacodynamics of a CYP2D6 substrate (S-YYYY) via mixed-effect modelling
|
Oscar Della Pasqua and Alan Maloney
When baseline matters. The presence of bias and inaccuracy in population parameter estimates derived from
|
John C. Lukas1, George L. Drusano2, Paolo Vicini1
Comparison of covariate models for Bayesian posterior pharmacokinetic parameter estimates from NONMEM with those from a n onparametric approach: Application to levofloxacin.
|
C. Della Pepa, M. Costa#, R. Canaparo, L. Serpe, GP. Zara, F. Casale, E. Berno and M. Eandi.
Analysis Of 5-Fu And Three Metabolites Concentration In Plasma Cancer Patients By Bayesian Autoclassificatio N Method.
|
Willi Weber, Lutz Harnisch
Learnings from a Population Pharmacokinetic Substudy of a Large Phase III Trial
|
J. A. Simpson1,2, R. Price1,3, F. ter Kuile3,4, P. Teja-Isavatharm5, F. Nosten1,2,3, T. Chongsuphajaisiddhi2, S. Looareesuwan2, L. Aarons5, N. J. White1,2
Population Pharmacokinetics of Mefloquine in patients with acute falciparum malaria
|
Michael Becka
An approach to non-linear kinetics using first-order characteristics
|
Michael Becka
An approach to non-linear kinetics using first-order characteristics
|
C Terret, E Erdociain, R Guimbaud, T Lafont, R Bugat, P Canal, E Chatelut
Inter- and intra-patient variabilities of Michaelis-Menten parameters of 5-fluorouracil
|
Georg Hempel 1,2, Nina Griese1,2, Petra Schulze Westhoff1, Dirk Reinhardt1, Ursula Creutzig1 and Joachim Boos1
Pharmacokinetics of Daunorubicin after Application of Liposomal Daunorubicin (Daunoxome®) in Children
|
Y.Merlé(1) and M. Tod(2)
Impact Of Model Linearization On The Accuracy Of Population Information Matrix And Optimal Design
|
Valle M, Drover D, Angst M, Verotta D.
Semi-Parametric Approach To Describe Hydromorphone Plasma Concentrations After The Administration Of Immediate And Controlled-Release Formulations
|
Emmanuelle Comets (1), France Mentré (1), Ryosei Kawai (2), Peter Marbach (2) and Jacky Vonderscher (2).
Evaluation of tests based on individual versus population modelling to compare dissolution curves
|
Vladimir K. Piotrovsky, Achiel Van Peer
Cardiovascular Safety Data Analysis via Mixed-Effects Modelling
|
Vladimir K. Piotrovsky, Achiel Van Peer
Separating Responders and Non-responders Using A Mixture of Distributions: An Example of Count Response
|
M.J. Garrido1, M van den Haak, M Danhof and P-H van der Graaf2
Population Pharmacokinetics of the Low-Efficacy Opioid receptor Agonists: Butorphanol and Nalbuphine
|
Mangues MA1, Trocóniz IF2, Soy D3, Alba G1, García M1, Ginovart G4.
Population Pharmacokinetics of Gentamicin in Neonates
|
Ho-Nguyen T.X.Q1., Girard P2.,Chabaud S2., Munafo A1.
Population pharmacokinetic analysis of recombinant human Chorionic Gonadotrophin (Ovidrel) compared with that of urinary human Chorionic Gonadotrophin (Profasi) in women undergoing superovulation
|
Ulrika Wählby, E. Niclas Jonsson and Mats O. Karlsson
Assessment of actual significance levels for covariate model building using NONMEM
|
G. Graham1, I. Nestorov1, L. Aarons2
Application Of Optimal Design For Categorical Pharmacodynamic Measures In Clinical Trials.
|
E Capparelli, J Connor, J Lane, Ja Englund, P Palumbo, C Baker and PAGTG 152 Team.
Population Pharmacokinetics and Pharmacodynamics of Zidovudine HIV Infected Infants and Children
|
J.A. Dowell, Ph.D., S.P. King, Ph.D., H.Liu, Ph.D., M.S. Berger, M.D., and J.M. Korth-Bradley, Pharm.D., Ph.D.
A Population Pharmacokinetic Analysis Of A New Antibody Chemotherapeutic Agent: Gemtuzumab Ozogamicin.
|
Roger W. Jelliffe1 and David S. Bayard2
An Interactive Multiple Model (Imm) Estimation Approach To Updating Posteriors In Pharmocokinetic Models Having Changing Parameter Values
|
S. Jönsson* and M.O. Karlsson
A Strategy For Selection Of Dose Sizes And Dosing Algorithm Based On A Real Data Example
|
R.A.A. Mathôt1, R.P.G. van Heeswijk1, H.J. Scherpbier2, L.A. de Koning3, H.S.A. Heymans2, J.M.A. Lange3, J.H. Beijnen1, R.M.W. Hoetelmans1
Population Pharmacokinetics Of Nelfinavir In HIV-1-Infected Children
|
Charlotte van Kesteren1, Ron A.A. Mathôt1, Luis López-Lázaro2, Esteban Cvitkovic3, Jose M. Jimeno2, Jos H. Beijnen1
Population pharmacokinetics of the novel marine derived anti-cancer agent Ecteinascidin 743 in a phase I study using non-linear mixed effects modelling.
|
R.A.J.Wixley
Use of Phase I PK/PD results in design and analysis of Clinical trials with Sparse data
|
Ken-ichi Sako , Kimikazu Shinozaki
Application of population approach to TDM services and educational programs
|
E. Niclas Jonsson, Lars Lindbom, Jakob Ribbing and Mats O. Karlsson
Perl-speaks-NONMEM (PsN) - a perl library of support functions for NONMEM related programming.
|
M. de Hoog1,2,, A.A.T.M.M. Vinks4, R.C. Schoemaker2,3, J.N. van den Anker1,2
Pharmacokinetic modeling of tobramycin in neonates: a comparison of NONMEM and NPEM2
|
Pérez-Ruixo, JJ; Casabó, VG; Merino, M; Llopis, MC; Jiménez, NV.
Population Pharmacokinetic And Pharmacodynamic Of Cyclophosphamide In Breast Cancer.
|
Martín-Suárez A1, Falcao AC2, Outeda M 3, Mora F4, González MC5, Quero M5, Arranz I4, Lanao JM1
Kinetic behaviour of digoxin in a paediatric population
|
LJ Van Obbergh, A Robert, F Veyckemans, F Roelants, RK Verbeeck.
Population Pharmacokinetics Of Ropivacaine Injected Caudally In Infants And Children
|
